{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:46:17Z","timestamp":1792277177609,"version":"4.4.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":259,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Dermatol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1111\/ced.12488","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T11:48:47Z","timestamp":1418730527000},"page":"142-145","source":"Crossref","is-referenced-by-count":5,"title":["Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine"],"prefix":"10.1093","volume":"40","author":[{"given":"A. D.","family":"Lock","sequence":"first","affiliation":[{"name":"Department of Dermatology; Royal Free London NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Haematology; Royal Free London NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H. A.","family":"Rustin","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Royal Free London NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"key":"10.1111\/ced.12488-BIB0001|ced12488-cit-0001","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.23459","article-title":"Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Pardanani","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1111\/ced.12488-BIB0002|ced12488-cit-0002","first-page":"54","volume-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues","author":"Horny","year":"2008","edition":"4"},{"key":"10.1111\/ced.12488-BIB0003|ced12488-cit-0003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000085563","article-title":"Clonality and molecular pathogenesis of mastocytosis","volume":"114","author":"Akin","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1111\/ced.12488-BIB0004|ced12488-cit-0004","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1111\/ced.12488-BIB0005|ced12488-cit-0005","first-page":"1993","volume-title":"Dermatology","author":"Bolognia","year":"2012"},{"key":"10.1111\/ced.12488-BIB0006|ced12488-cit-0006","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S8756-3282(02)00875-X","article-title":"A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men","volume":"31","author":"Brumsen","year":"2002","journal-title":"Bone"},{"key":"10.1111\/ced.12488-BIB0007|ced12488-cit-0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2008.07038.x","article-title":"Thalidomide in advanced mastocytosis","volume":"141","author":"Damaj","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1111\/ced.12488-BIB0008|ced12488-cit-0008","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1111\/ced.12488-BIB0009|ced12488-cit-0009","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2703.2703","article-title":"A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis","volume":"108","author":"Hochhaus","year":"2006","journal-title":"Blood"},{"key":"10.1111\/ced.12488-BIB0010|ced12488-cit-0010","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.316.316","article-title":"KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. ASH Annual Meeting Abstracts","volume":"116","author":"Gotlib","year":"2010","journal-title":"Blood"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fced.12488","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ced.12488\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T22:23:41Z","timestamp":1717626221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/40\/2\/142\/6621344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,16]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.12488","relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12,16]]}}}